⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL11601657 | 0.90 | CHRNB2 (0.50) | — | |
| SCHEMBL16244490 | 0.85 | TSHR (0.41) | — | |
| SCHEMBL7765958 | 0.83 | — | — | |
| SCHEMBL1766714 | 0.81 | — | — | |
| SCHEMBL2547540 | 0.81 | LMNA (0.57) | — | |
| SCHEMBL7769338 | 0.79 | LMNA (0.42) | — | |
| SCHEMBL16244292 | 0.79 | LMNA (0.42) | — | |
| SCHEMBL30525718 | 0.78 | LMNA (0.62) | — | |
| SCHEMBL4614898 | 0.77 | — | — | |
| SCHEMBL26107013 | 0.76 | CHRNB2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | claimed |
| EP-4688790-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260028353-A1 | MACROCYCLIC RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-01-29 | — | — | US | claimed |
| CN-115873020-B | RAS inhibitors | 锐新医药公司 | 2025-06-13 | — | — | CN | claimed |
| US-12252497-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-03-18 | — | — | US | claimed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | claimed |
| WO-2024249299-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-12-05 | — | — | WO | claimed |
| CN-118852330-A | RAS inhibitors for the treatment of cancer | 锐新医药公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2024211712-A1 | CONDENSED MACROCYCLIC COMPOUNDS AS RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-10-10 | — | — | WO | claimed |
| CN-101671278-B | Carbamic acid alkannin ester as well as preparation method and application thereof | UNIV ZHEJIANG | 2012-06-27 | — | — | CN | claimed |
| CN-102239158-A | Method for preparing a spiroindoline and a precursor thereof | GLAXO GROUP LTD | 2011-11-09 | — | — | CN | claimed |
| WO-2011073277-A1 | PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | claimed |
| WO-2011073273-A1 | BENZOXAZINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | claimed |
| CN-101671278-A | Carbamic acid alkannin ester as well as preparation method and application thereof | UNIV ZHEJIANG | 2010-03-17 | — | — | CN | claimed |
| US-6319310-B1 | FOR ACOUSTIC INK JET PRINTING; TRANSPARENCY, GLOSS, CREASE RESISTANCE | XEROX CORPORATION | 2001-11-20 | — | — | US | claimed |
| US-6288141-B1 | Ink compositions | XEROX CORPORATION | 2001-09-11 | — | — | US | claimed |
| US-6132499-A | Inks | XEROX CORPORATION (US) | 2000-10-17 | — | — | US | claimed |
| US-6071333-A | Ink compositions | XEROX CORPORATION (US) | 2000-06-06 | — | — | US | claimed |
| US-6045607-A | FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING | XEROX CORPORATION (US) | 2000-04-04 | — | — | US | claimed |